Anthony H. Futerman - Nanotechnology

Author Information

Anthony H. Futerman is a distinguished researcher affiliated with the Department of Biomolecular Sciences at the Weizmann Institute of Science in Rehovot, Israel. His extensive work in the field of lipid metabolism, neurobiology, and biochemistry has significantly contributed to our understanding of various lipid-related diseases and cellular processes.

Research Contributions

Anthony H. Futerman has made substantial contributions to the field of lipid metabolism and neurobiology. His recent research includes studies on lipid changes in iPSC-derived neurons, the interaction between fatty acid transport protein 2 and ceramide synthase 2, and the impact of GBA mutations on Parkinson's disease. His work also delves into the biophysical impact of abnormal lipid accumulation in Niemann-Pick disease type C, signaling pathways in Gaucher disease, and the role of sphingolipids in cellular functions. His research often employs advanced proteomics and live cell imaging techniques to elucidate the mechanisms underlying these conditions.

Aliases

Anthony H. Futerman is also known by several aliases, including Anthony Futerman, A. Futerman, A. H. Futerman, Anthonyh. Futerman, and A Futerman.

Publication and Citation Metrics

Metric	Value
Citation Count	19,054
h-index	76
Paper Count	334

Publications:

16pdel lipid changes in iPSC-derived neurons and function of FAM57B in lipid metabolism and synaptogenesis

DOI: 10.1016/j.isci.2021.103551

Year: 2022

Fatty acid transport protein 2 interacts with ceramide synthase 2 to promote ceramide synthesis

DOI: 10.1016/j.jbc.2022.101735

Year: 2022

Laurdan in live cell imaging: Effect of acquisition settings, cell culture conditions and data analysis on generalized polarization measurements.

DOI: 10.1016/j.jphotobiol.2022.112404

Year: 2022

GBA mutations, glucosylceramide and Parkinson's disease

DOI: 10.1016/j.conb.2021.11.004

Year: 2022

c-Abl activates RIPK3 signaling in Gaucher disease.

DOI: 10.1016/j.bbadis.2021.166089

Year: 2021

Biophysical impact of sphingosine and other abnormal lipid accumulation in Niemann-Pick disease type C cell models.

DOI: 10.1016/j.bbalip.2021.158944

Year: 2021

In Memoriam: Dan Tawfik

DOI: 10.37282/991819.21.39

Year: 2021

Proteomics analysis of a human brain sample from a mucolipidosis type IV patient reveals pathophysiological pathways

DOI: 10.1186/s13023-021-01679-7

Year: 2021

Ceramide turnover in GtoPdb v.2021.3

DOI: 10.2218/gtopdb/f767/2021.3

Year: 2021

Sphingolipids

DOI: 10.1016/b978-0-12-824048-9.00009-2

Year: 2021

How can inventors maximize the benefits of the PCT in Nanotechnology?

How is PDMS Used in Microfluidics?

How is Nanotechnology Classified in the IPC System?

Are There Specific Guidelines for Nanomaterials?

What are the Challenges in Working with Oxide Films?

How is Nano Silver Synthesized?

What is the Future of Nanomanufacturing?

What is the Hartree-Fock Method?

Why is NMR Spectroscopy Important in Nanotechnology?

What Techniques are Used to Study Evaporation at the Nanoscale?

Partnered Content Networks

Relevant Topics